Please provide your email address to receive an email when new articles are posted on . Symvess is a sterile, cell-free tissue engineered vessel made of human extracellular matrix proteins.

Humacyte, Inc. has announced that the FDA has granted full approval for SYMVESS, a novel bioengineered human tissue designed for use as a vascular conduit in patients with extremity arterial ...

The US Food and Drug Administration has approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent ...

(Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the U.S. Food and Drug Administration (FDA) ...

today announced that the U.S. Food and Drug Administration (FDA) has granted a full approval for SYMVESS (acellular tissue engineered vessel-tyod) for use in adults as a vascular conduit for ...

Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit ...

Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...

Fox. “SYMVESS shows promise to reduce amputation rates since an alternative conduit for war injuries is often needed but up until now has not been a good option.” “The FDA approval of ...

STORY HIGHLIGHTS FDA approved Humacyte's Symvess for vascular trauma treatment. Symvess is a bioengineered human tissue vascular conduit. Humacyte plans commercial launch and technology expansion.